Steven Cohen Uro Gen Pharma Ltd. Call Options Transaction History
Point72 Asset Management, L.P.
- $36 Billion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding URGN
# of Institutions
119Shares Held
39.3MCall Options Held
158KPut Options Held
161K-
Rtw Investments, LP New York, NY3.56MShares$46.7 Million1.0% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA3.3MShares$43.3 Million0.11% of portfolio
-
Ra Capital Management, L.P. Boston, MA3.08MShares$40.5 Million0.78% of portfolio
-
Great Point Partners LLC Greenwich, CT2.91MShares$38.1 Million12.93% of portfolio
-
Menora Mivtachim Holdings Ltd.2.3MShares$30.2 Million0.27% of portfolio
About UroGen Pharma Ltd.
- Ticker URGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 22,740,500
- Market Cap $298M
- Description
- UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead...